HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Participants who had protein bars enriched with collagen not only saw greater weight loss results but also improved ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

A North Texas woman with a cautionary tale warns others to do their research before starting popular weight loss drugs.

A detailed AquaSculpt review highlighting its ingredient list, formulation, and scientific rationale A breakdown of the ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

after the drugmaker reported positive results from a late-stage trial of a GLP-1 treatment for Type 2 diabetes and obesity in pill form. The last time the stock rose as much was June 29 ...

Sophia Umansky—the daughter of Kyle Richards and Mauricio Umansky—doubled down on her decision to take Mounjaro, despite ...

Fat burners come in various forms, such as thermogenics, appetite suppressants, and carb blockers, allowing women to choose ...